1. Home
  2. CSBR vs ATYR Comparison

CSBR vs ATYR Comparison

Compare CSBR & ATYR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • CSBR
  • ATYR
  • Stock Information
  • Founded
  • CSBR 1985
  • ATYR 2005
  • Country
  • CSBR United States
  • ATYR United States
  • Employees
  • CSBR N/A
  • ATYR N/A
  • Industry
  • CSBR Biotechnology: Biological Products (No Diagnostic Substances)
  • ATYR Biotechnology: Biological Products (No Diagnostic Substances)
  • Sector
  • CSBR Health Care
  • ATYR Health Care
  • Exchange
  • CSBR Nasdaq
  • ATYR Nasdaq
  • Market Cap
  • CSBR 90.2M
  • ATYR 105.8M
  • IPO Year
  • CSBR 1986
  • ATYR 2015
  • Fundamental
  • Price
  • CSBR $6.48
  • ATYR $1.02
  • Analyst Decision
  • CSBR Strong Buy
  • ATYR Buy
  • Analyst Count
  • CSBR 1
  • ATYR 6
  • Target Price
  • CSBR $12.00
  • ATYR $8.88
  • AVG Volume (30 Days)
  • CSBR 15.1K
  • ATYR 12.3M
  • Earning Date
  • CSBR 09-15-2025
  • ATYR 11-06-2025
  • Dividend Yield
  • CSBR N/A
  • ATYR N/A
  • EPS Growth
  • CSBR N/A
  • ATYR N/A
  • EPS
  • CSBR 0.21
  • ATYR N/A
  • Revenue
  • CSBR $56,878,000.00
  • ATYR N/A
  • Revenue This Year
  • CSBR $7.31
  • ATYR $420.85
  • Revenue Next Year
  • CSBR $12.01
  • ATYR $1,513.40
  • P/E Ratio
  • CSBR $30.18
  • ATYR N/A
  • Revenue Growth
  • CSBR 10.11
  • ATYR N/A
  • 52 Week Low
  • CSBR $3.75
  • ATYR $0.68
  • 52 Week High
  • CSBR $11.99
  • ATYR $7.29
  • Technical
  • Relative Strength Index (RSI)
  • CSBR 47.59
  • ATYR 31.03
  • Support Level
  • CSBR $6.29
  • ATYR $0.90
  • Resistance Level
  • CSBR $6.79
  • ATYR $1.10
  • Average True Range (ATR)
  • CSBR 0.25
  • ATYR 0.09
  • MACD
  • CSBR 0.03
  • ATYR 0.18
  • Stochastic Oscillator
  • CSBR 33.83
  • ATYR 68.48

About CSBR Champions Oncology Inc.

Champions Oncology Inc is a USA based company which is engaged in the development and sale of state of the art technology solutions and products to personalize the development and use of oncology drugs. The company operates through one segment namely Personalized Oncology Solutions (POS) and Translational Oncology Solutions (TOS). Its POS business assists physicians in developing personalized treatment options for their cancer patients through tumor-specific data obtained from drug panels and related personalized oncology services. The TOS business assists pharmaceutical and biotechnology companies with their drug development process and offers studies or license tumors for use in studies. The company's revenue is majorly derived from research services.

About ATYR aTyr Pharma Inc. Common Stock

aTyr Pharma Inc is a biotherapeutics company engaged in the discovery and development of first-in-class medicines from its proprietary tRNA synthetase platform. The company has concentrated its research and development efforts on a newly discovered area of biology, the extracellular functionality and signaling pathways of tRNA synthetases. Its primary focus is efzofitimod, a clinical-stage product candidate which targets NRP2 to resolve chronic inflammation that can cause to fibrosis. Efzofitimod has a novel mechanism of action for potentially treating lung inflammation and fibrosis.

Share on Social Networks: